Company intelligence

Hengrui Pharmaceuticals

BiotechActive

Is this your company? Get featured or correct your listing →

Suggest a correction

We're still building this profile — here is what Pulse has covered.

Latest Pulse

  1. Braveheart Bio Prices Upsized $382.5M IPO on NasdaqBraveheart Bio priced its IPO at $18 a share, above range, raising $382.5M for a cardiovascular drug licensed from China's Hengrui Pharmaceuticals -- a sign the biotech IPO window is reopening after two rough years.→

Coverage Timeline

newest first
  1. Aug 6, 2026IPOBraveheart Bio Prices Upsized $382.5M IPO on Nasdaq$382.5M IPO→

All Coverage

IPO

Braveheart Bio Prices Upsized $382.5M IPO on Nasdaq

Braveheart Bio Prices Upsized $382.5M IPO on Nasdaq logo
IPO$382.5M IPO

Braveheart Bio Prices Upsized $382.5M IPO on Nasdaq

Braveheart Bio priced its IPO at $18 a share, above range, raising $382.5M for a cardiovascular drug licensed from China's Hengrui Pharmaceuticals -- a sign the biotech IPO window is reopening after two rough years.

BRIEF

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsIambic TherapeuticsApnimedRetension PharmaceuticalsEli Lilly